<DOC>
	<DOCNO>NCT00089479</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety Taxotere + Xeloda , versus Taxotere alone , follow regimen Adriamycin plus Cytoxan woman high-risk breast cancer . Following 4 cycle Adriamycin Cytoxan , patient randomize receive either 1 ) Taxotere 75mg/m2 iv day 1 Xeloda 825mg/m2 po bid day 1-14 3 week cycle 2 ) Taxotere 100mg/m2 iv alone day 1 3 week cycle . The anticipated time study treatment disease progression , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Women With High-Risk Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>female patient 1870 year age ; adenocarcinoma breast ; previous invasive breast cancer diagnose &gt; 5 year enter study ; evidence metastatic disease . history severe hypersensitivity reaction Taxotere ; previous treatment anthracycline , anthracenedione ( mitoxantrone ) , taxane ; treatment fluoropyrimidine ( 5fluorouracil ) within last 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>